To address these dichotomies, future strategies should incorporate biomarker stratification (e.g., mutational status and hypoxia signatures), combinatorial approaches with immune checkpoint inhibitors to counter microenvironmental resistance, and development of isoform‐specific inhibitors to preserve tumor‐suppressive SIRT1 functions in normal tissues. Here, SIRT1 is linked to neoplasm.